In vivo angiogenesis assay

• US 5,382,514 A
• Filed: 03/31/1992
• Issued: 01/17/1995
• Est. Priority Date: 03/31/1992
• Status: Expired due to Term

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Inventors: Passaniti, Antonino, Martin, George R.
• Primary Examiner(s): Scheiner, Toni R.
• Application Number:
  US07/862,622
• Time in Patent Office: 1,022 Days
• Field of Search: 435/7.23, 435/7.21, 435/29, 436/63, 436/64, 436/813, 424/9, 424/85.1, 424/520, 424/572
• US Class Current: 435/7.21
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: Y10S 436/813 Cancer

Abstract

A method of performing in vivo angiogenesis assays which involves the use of a matrix material which can be maintained in an injectable solution form at a temperature below that of a host and which forms a gel matrix when injected into a host. The matrix material is an extract of murine basement membrane. Angiogenic factors, including inducers and inhibitors can be added to the matrix material prior to injection into a host. After a period of time within the host, the gel matrix is recovered and angiogenesis of the recovered matrix gel is quantitated. The procedure can be used to induce vascularization or inhibit vascularization at a tissue situs as desired.

Claims

1. A method of performing an in vivo angiogenesis assay which comprises:

providing a liquid matrix material which forms a matrix gel when injected into a host wherein said liquid matrix material is MATRIGEL;

adding an angiogenesis inducing or inhibiting agent to said liquid matrix material;

injecting said liquid matrix material containing said angiogenesis inducing or inhibiting agent into a host to form a matrix gel;

recovering said matrix gel from said host; and

quantitating angiogenesis of said recovered matrix gel.

2. A method of performing an in vivo angiogenesis assay according to claim 1 wherein said angiogenesis quantitating includes quantitating vessel formation.

3. A method of performing an in vivo angiogenesis assay according to claim 2 wherein said angiogenesis quantitating includes determining hemoglobin content.

4. A method of performing an in vivo angiogenesis assay according to claim 1 wherein said angiogenesis quantitating includes isolating endothelial cells which penetrate said gel matrix.

5. A method of performing an in vivo angiogenesis assay according to claim 1, wherein said angiogenesis inducing agent is selected from the group consisting of fibroblast growth factor (FGF), heparin and mixtures thereof.

6. A method of inducing vascularization in a tissue situs which comprises:

providing a liquid matrix material which forms a matrix gel when injected into a host wherein said liquid matrix material is MATRIGEL;

adding an angiogenic inducing agent to said liquid matrix material; and

injecting said liquid matrix material containing said angiogenic inducing agent into a tissue situs of a host to form a matrix gel.

7. A method of inducing vascularization in a tissue situs according to claim 6, wherein said tissue situs comprises a wound.

8. A method of inducing vascularization in a tissue situs according to claim 6, wherein said tissue situs comprises an area of ischemic tissue.

9. A method of inhibiting vascularization in a tissue situs which comprises:

providing a liquid matrix material which forms a matrix gel when injected into a host wherein said liquid matrix material is MATRIGEL;

adding an angiogenic inhibiting agent to said liquid matrix material; and

injecting said liquid matrix material containing said angiogenic inhibiting agent into a tissue situs of a host to form a matrix gel.

10. A method of inhibiting vascularization in a tissue situs according to claim 9, wherein said tissue situs comprises a site of augmented angiogenesis.